Related Experiment Videos
Alfa-antitrypsin increase in lung cancer
Bollettino Dell'Istituto Sieroterapico Milanese
|January 1, 1976
Summary
Alpha-1-antitrypsin (A1AT) levels are significantly elevated in over 90% of lung cancer patients. These A1AT levels correlate with disease progression and decrease with chemotherapy, but rebound after treatment cessation.
Area of Science:
- Oncology
- Pulmonology
- Biochemistry
Background:
- Alpha-1-antitrypsin (A1AT) is a proteinase inhibitor with potential roles in inflammation and cancer.
- Elevated A1AT levels have been observed in various inflammatory conditions and some malignancies.
Purpose of the Study:
- To investigate the serum content of A1AT in patients diagnosed with lung cancer (L.Ca.).
- To compare A1AT levels in lung cancer patients against various control groups, including other lung diseases and neoplastic conditions.
Main Methods:
- Serum samples from 100 lung cancer patients were analyzed for A1AT content.
- Control groups included patients with metastatic lung neoplasms, sarcomatosis, acute bronchopneumonia, bronchiectasis, emphysema, and non-neoplastic pleural fluid samples.
Main Results:
- Over 90% of lung cancer patients exhibited significantly higher serum A1AT levels compared to controls.
- A1AT levels showed a positive correlation with the worsening of the lung cancer condition.
- Chemotherapy reduced A1AT levels, with levels increasing again after treatment discontinuation.
Conclusions:
- Elevated serum A1AT is a strong indicator in over 90% of lung cancer cases.
- Serum A1AT levels may serve as a potential biomarker for monitoring disease progression and treatment response in lung cancer.